Lymphoma News

A pathfinder spaceflight investigation has flown to the International Space Station with a goal of expanding a population of hematopoietic stem cells that retain their multipotency.

CHICAGO — Researchers presented the maximum dose for indenoisoquinoline LMP744 during the ASCO Annual Meeting, reporting prolonged stability in select patients.

CHICAGO — In this video, Emanuele Zucca, MD, discusses the IELSG37 trial supporting the omission of mediastinal radiotherapy in patients with primary mediastinal B-cell lymphoma who achieve complete metabolic response after chemotherapy.

Christopher Flowers, MD, has been appointed division head of cancer medicine at The University of Texas MD Anderson Cancer Center.

The FDA announced several regulatory actions the past few weeks.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

Insurance and neighborhood socioeconomic status were significant mediators of inequity in CV mortality among Black and white cancer survivors, according to a study published in the International Journal of Epidemiology.

In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab maintenance for young patients with mantle cell lymphoma.

An analysis of online conversations among health care professionals on social media in June revealed overwhelming support for FDA approvals of therapies for prostate cancer and lymphoma.

CHICAGO — Negative circulating tumor DNA status contributed to a PFS benefit for patients with previously untreated diffuse large B-cell lymphoma, according to research presented at ASCO Annual Meeting.